Division of Nephrology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
J Tradit Chin Med. 2023 Feb;43(1):6-13. doi: 10.19852/j.cnki.jtcm.2023.01.004.
: To collect data and investigate the effects of Huangkui capsule (黄葵胶囊, HKC) on chronic kidney disease (CKD).
: PubMed, Embase, Cochrane Library, and three Chinese databases (China National Knowledge Infrastructure, Wanfang, and China Science and Technology Journal Database) were searched for articles published until October 2020. Randomized controlled trials (RCTs) of HKCs used for treating CKD were reviewed. Data were organized and analyzed using RevMan 5.3 software.
: HKC significantly lowered the blood urea nitrogen (BUN) level [mean difference () = －2.26; 95% confidence interval (), －2.91 to －1.61], serum creatinine level ( = －17.45; 95% , －22.29 to －12.60), and 24-h urine protein content ( = －0.73; 95% , －1.00 to －0.46) and improved the glomerular filtration rate (GFR) ( = 10.69; 95% , 5.57 to 15.81) and serum albumin level ( = 2.20; 95% , 0.49 to 3.90).
: Our findings show that HKC could lower the BUN level, serum creatinine level, and 24-h urine protein content. HKC also improved GFR and serum albumin levels. However, high-quality RCTs in other countries with larger sample sizes are warranted to confirm these findings.
收集数据并探讨黄葵胶囊（HKC）治疗慢性肾脏病（CKD）的效果。
检索PubMed、Embase、Cochrane 图书馆和三个中文数据库（中国知网、万方和中国科技期刊数据库），截至 2020 年 10 月，纳入黄葵胶囊治疗 CKD 的随机对照试验（RCT）。采用 RevMan 5.3 软件对数据进行整理和分析。
黄葵胶囊可显著降低血尿素氮（BUN）水平[均数差（MD）＝－2.26；95%置信区间（CI）：－2.91 至－1.61]、血清肌酐水平（MD ＝－17.45；95%CI：－22.29 至－12.60）和 24 小时尿蛋白含量（MD ＝－0.73；95%CI：－1.00 至－0.46），并提高肾小球滤过率（GFR）（MD ＝10.69；95%CI：5.57 至 15.81）和血清白蛋白水平（MD ＝2.20；95%CI：0.49 至 3.90）。
我们的研究结果表明，黄葵胶囊可降低 BUN 水平、血清肌酐水平和 24 小时尿蛋白含量，还可提高 GFR 和血清白蛋白水平。然而，需要其他国家开展高质量、大样本 RCT 来进一步验证这些发现。
